Health Condition 1: null- Type 2 Diabetes Mellitus
Conditions
Interventions
Intervention1: Tab Adipomimetin (80 mg active): Active of the drug 80 mg four times per day for 90 days
Control Intervention1: Tab Adipomimetin (40 mg active): Active of the drug will be in the dose o
Sponsors
Phytabolites Neutraceuticals Pvt Ltd
Eligibility
Inclusion criteria
Inclusion criteria: 1.A freshly detected diabetic or on oral anti-diabetic treatment 2.No change in anti-diabetic treatment for the last one month if not detected DM in last month 3.Fasting plasma glucose not exceeding 180mg/dL 4.Between Age group of 18 and 60 years 5.Both male and female patients will be included 6.Patients consenting in writing
Exclusion criteria
Exclusion criteria: 1.Diabetes other than type 2 diabetes mellitus 2.Patients having complications of diabetes like diabetic neuropathy, retinopathy, nephropathy, ketoacidosis. 3.Participation in any other clinical trial within the last 30 days 4.Pregnant or breast-feeding woman 5.Patient with acute conditions like Appendicitis 6.Participant of other clinical trial
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To determine effective dose for reducing blood sugar levels.Timepoint: Telephonic Follow up at day 45 and day 75. Clinical follow up at day 15, day 30, day 60 and day 90. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1.To see efficacy of Tab. Adipomimetinin enhancing the Quality of Life of patients with T2DM 2.To see overall safety of Tab. Adipomimetinin patients with T2DM Timepoint: Telephonic Follow up at day 45 and day 75. Clinical follow up at day 15, day 30, day 60 and day 90. | — |
Countries
India
Contacts
Public ContactDr Sharvari Rangnekar
Quest Clinical Services
Outcome results
None listed